CureVac, Yale Collaborate on Discovery Research

Will focus on developing novel mRNA-based candidates for pulmonary diseases

CureVac AG has entered into a Collaborative Research Agreement (CRA) with Yale University for discovery research into mRNA-based pulmonary therapeutic candidates.    The exclusive CRA covers the development of an undisclosed number of novel mRNA-based candidates for pulmonary diseases. Under terms of the CRA, the Yale University team will perform discovery research on targets related to pulmonary diseases and present therapeutic candidates to CureVac for preclinical and subsequent clinical dev...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters